Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 4
1946 4
1947 1
1948 3
1949 2
1950 2
1951 3
1952 1
1953 1
1955 2
1956 2
1958 2
1959 5
1960 12
1961 4
1962 7
1963 3
1964 7
1965 7
1966 10
1967 11
1968 6
1969 12
1970 9
1971 6
1972 6
1973 3
1974 5
1975 4
1976 3
1977 1
1978 1
1979 3
1980 1
1981 2
1982 3
1983 2
1986 4
1988 1
1989 1
1991 1
1993 1
1994 3
1996 2
1997 4
1998 3
1999 5
2001 4
2002 4
2003 2
2004 1
2005 5
2006 1
2007 14
2008 8
2009 5
2010 6
2011 2
2012 3
2013 10
2014 10
2015 9
2016 9
2017 8
2018 6
2019 8
2020 8
2021 13
2022 5
2023 7
2024 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

322 results

Results by year

Filters applied: . Clear all
Page 1
Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records.
Bell CF, Gibbons DC, Drysdale M, Birch HJ, Lloyd EJ, Patel V, Carpenter C, Carlson K, Calay ES, Puranik A, Wagner TE, O'Horo JC, Razonable RR. Bell CF, et al. Among authors: birch hj. PLoS One. 2024 Jul 16;19(7):e0304822. doi: 10.1371/journal.pone.0304822. eCollection 2024. PLoS One. 2024. PMID: 39012863 Free PMC article.
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: a retrospective cohort study.
Patel V, Yarwood MJ, Levick B, Gibbons DC, Drysdale M, Kerr W, Watkins JD, Young S, Pierce BF, Lloyd EJ, Birch HJ, Kamalati T, Brett SJ. Patel V, et al. Among authors: birch hj. Curr Med Res Opin. 2024 Aug;40(8):1323-1334. doi: 10.1080/03007995.2024.2376144. Epub 2024 Jul 8. Curr Med Res Opin. 2024. PMID: 38975862
Characterizing health-related quality of life and identifying disease predictors among patients suspected of having long COVID: an analysis of COMET-ICE clinical trial data.
Gelhorn HL, Ghafoori P, Cutts K, Birch H, Savva Y, Satram S, Lloyd E, Chen WH. Gelhorn HL, et al. Among authors: birch h. Front Public Health. 2024 May 9;12:1278106. doi: 10.3389/fpubh.2024.1278106. eCollection 2024. Front Public Health. 2024. PMID: 38784592 Free PMC article. Clinical Trial.
Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study.
Drysdale M, Galimov ER, Yarwood MJ, Patel V, Levick B, Gibbons DC, Watkins JD, Young S, Pierce BF, Lloyd EJ, Kerr W, Birch HJ, Kamalati T, Brett SJ. Drysdale M, et al. Among authors: birch hj. BMJ Open Respir Res. 2024 Apr 4;11(1):e002238. doi: 10.1136/bmjresp-2023-002238. BMJ Open Respir Res. 2024. PMID: 38575338 Free PMC article.
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).
Bell CF, Bobbili P, Desai R, Gibbons DC, Drysdale M, DerSarkissian M, Patel V, Birch HJ, Lloyd EJ, Zhang A, Duh MS; N3C consortium. Bell CF, et al. Among authors: birch hj. Clin Drug Investig. 2024 Mar;44(3):183-198. doi: 10.1007/s40261-024-01344-4. Epub 2024 Feb 20. Clin Drug Investig. 2024. PMID: 38379107 Free PMC article.
322 results